Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen (271 views)
Oncotargets Ther (ISSN: 1178-6930, 1178-6930linking), 2015 Jun 8; 8: 1345-1349.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.272, 5-year impact factor: 2.235
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84934343729&partnerID=40&md5=dc655fe2ce94fbebb53e050613680136
Keywords: Adjuvant Treatment, Local Control, Three-Dimensional Conformal Radiotherapy, Thymoma, Toxicity,
Affiliations:
*** IBB - CNR ***
Medical Oncology Unit, POC S Annunziata, Taranto, Italy
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
Institute of Biostructures and Bioimaging, National Council of Research, Naples, Italy
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, United States
Division of Oncology, Centro di riferimento Oncologico di Basilicata, IRCCS Rionero in Vulture, Potenza, Italy
Department of Radiotherapy, Istituto Nazionale per la Cura dei Tumori-Fondazione G. Pascale. IRCCS di Napoli, Naples, Italy
Commonwealth Scientific \& Industrial Research Organisation (CSIRO)
Consiglio Nazionale delle Ricerche (CNR)
Fdn G Pascale IRCCS Napoli
References:
National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology, , http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, (NCCN guidelines version I. 2014). Accessed February 20, 201
Eng, T.Y., Fuller, C.D., Jagirdar, J., Bains, Y., Thomas, C.R., Jr., Thymic carcinoma: State of the art review (2004) Int J Radiat Oncol Biol Phys., 59 (3), pp. 654-664
Koppitz, H., Rockstroh, J.K., Schüller, H., State-of-the-art classification and multimodality treatment of malignant thymoma (2012) Cancer Treat Rev., 38 (5), pp. 540-548
Kondo, K., Optimal therapy for thymoma (2008) J Med Invest., 55 (1-2), pp. 17-28
Gomez, D., Komaki, R., Yu, J., Ikushima, H., Bezjak, A., Radiation therapy definitions and reporting guidelines for thymic malignancies (2011) J Thorac Oncol., 6 (7), pp. S1743-S1748
Utsumi, T., Shiono, H., Kadota, Y., Postoperative radiation therapy after complete resection of thymoma has little impact on survival (2009) Cancer., 115 (23), pp. 5413-5420
Korst, R.J., Kansler, A.L., Christos, P.J., Mandal, S., Adjuvant radiotherapy for thymic epithelial tumors: A systematic review and meta-analysis (2009) Ann Thorac Surg., 87 (5), pp. 1641-1647
Eng, T.Y., Thomas, C.R., Jr., Radiation therapy in the management of thymic tumors (2005) Semin Thorac Cardiovasc Surg., 17 (1), pp. 32-40
Quintanilla-Martinez, L., Wilkins, E.W., Jr., Choi, N., Efird, J., Hug, E., Harris, N.L., Thymoma. Histologic subclassification is an independent prognostic factor (1994) Cancer., 74 (2), pp. 606-617
Ruffini, E., Mancuso, M., Oliaro, A., Recurrence of thymoma: Analysis of clinicopathologic features, treatment, and outcome (1997) J Thorac Cardiovasc Surg., 113 (1), pp. 55-63
Rena, O., Papalia, E., Oliaro, A., Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? (2007) Eur J Cardiothorac Surg., 31 (1), pp. 109-113
Mangi, A.A., Wright, C.D., Allan, J.S., Adjuvant radiation therapy for stage II thymoma (2002) Ann Thorac Surg., 74 (4), pp. 1033-1037
Haniuda, M., Morimoto, M., Nishimura, H., Kobayashi, O., Yamanda, T., Iida, F., Adjuvant radiotherapy after complete resection of thymoma (1992) Ann Thorac Surg., 54 (2), pp. 311-315
Yan, J., Liu, Q., Moseley, J.N., Adjuvant radiotherapy for stages II and III resected thymoma: A single-institutional experience (2014) Am J Clin Oncol., , In press
Sugie, C., Shibamoto, Y., Ikeya-Hashizume, C., Invasive thymoma: Postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination (2008) J Thorac Oncol., 3 (1), pp. 75-81
Komaki, R., Gomez, D.R., Radiotherapy for thymic carcinoma: Adjuvant, inductive, and definitive (2014) Front Oncol., 3, p. 330
Oncotargets Ther (ISSN: 1178-6930, 1178-6930linking), 2015 Jun 8; 8: 1345-1349.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.272, 5-year impact factor: 2.235
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84934343729&partnerID=40&md5=dc655fe2ce94fbebb53e050613680136
Keywords: Adjuvant Treatment, Local Control, Three-Dimensional Conformal Radiotherapy, Thymoma, Toxicity,
Affiliations:
*** IBB - CNR ***
Medical Oncology Unit, POC S Annunziata, Taranto, Italy
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
Institute of Biostructures and Bioimaging, National Council of Research, Naples, Italy
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, United States
Division of Oncology, Centro di riferimento Oncologico di Basilicata, IRCCS Rionero in Vulture, Potenza, Italy
Department of Radiotherapy, Istituto Nazionale per la Cura dei Tumori-Fondazione G. Pascale. IRCCS di Napoli, Naples, Italy
Commonwealth Scientific \& Industrial Research Organisation (CSIRO)
Consiglio Nazionale delle Ricerche (CNR)
Fdn G Pascale IRCCS Napoli
References:
National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology, , http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, (NCCN guidelines version I. 2014). Accessed February 20, 201
Eng, T.Y., Fuller, C.D., Jagirdar, J., Bains, Y., Thomas, C.R., Jr., Thymic carcinoma: State of the art review (2004) Int J Radiat Oncol Biol Phys., 59 (3), pp. 654-664
Koppitz, H., Rockstroh, J.K., Schüller, H., State-of-the-art classification and multimodality treatment of malignant thymoma (2012) Cancer Treat Rev., 38 (5), pp. 540-548
Kondo, K., Optimal therapy for thymoma (2008) J Med Invest., 55 (1-2), pp. 17-28
Gomez, D., Komaki, R., Yu, J., Ikushima, H., Bezjak, A., Radiation therapy definitions and reporting guidelines for thymic malignancies (2011) J Thorac Oncol., 6 (7), pp. S1743-S1748
Utsumi, T., Shiono, H., Kadota, Y., Postoperative radiation therapy after complete resection of thymoma has little impact on survival (2009) Cancer., 115 (23), pp. 5413-5420
Korst, R.J., Kansler, A.L., Christos, P.J., Mandal, S., Adjuvant radiotherapy for thymic epithelial tumors: A systematic review and meta-analysis (2009) Ann Thorac Surg., 87 (5), pp. 1641-1647
Eng, T.Y., Thomas, C.R., Jr., Radiation therapy in the management of thymic tumors (2005) Semin Thorac Cardiovasc Surg., 17 (1), pp. 32-40
Quintanilla-Martinez, L., Wilkins, E.W., Jr., Choi, N., Efird, J., Hug, E., Harris, N.L., Thymoma. Histologic subclassification is an independent prognostic factor (1994) Cancer., 74 (2), pp. 606-617
Ruffini, E., Mancuso, M., Oliaro, A., Recurrence of thymoma: Analysis of clinicopathologic features, treatment, and outcome (1997) J Thorac Cardiovasc Surg., 113 (1), pp. 55-63
Rena, O., Papalia, E., Oliaro, A., Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? (2007) Eur J Cardiothorac Surg., 31 (1), pp. 109-113
Mangi, A.A., Wright, C.D., Allan, J.S., Adjuvant radiation therapy for stage II thymoma (2002) Ann Thorac Surg., 74 (4), pp. 1033-1037
Haniuda, M., Morimoto, M., Nishimura, H., Kobayashi, O., Yamanda, T., Iida, F., Adjuvant radiotherapy after complete resection of thymoma (1992) Ann Thorac Surg., 54 (2), pp. 311-315
Yan, J., Liu, Q., Moseley, J.N., Adjuvant radiotherapy for stages II and III resected thymoma: A single-institutional experience (2014) Am J Clin Oncol., , In press
Sugie, C., Shibamoto, Y., Ikeya-Hashizume, C., Invasive thymoma: Postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination (2008) J Thorac Oncol., 3 (1), pp. 75-81
Komaki, R., Gomez, D.R., Radiotherapy for thymic carcinoma: Adjuvant, inductive, and definitive (2014) Front Oncol., 3, p. 330
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen
Background: The clinical benefits of postoperative radiation therapy (PORT) for patients with thymoma are still controversial. In the absence of defined guidelines, prognostic factors such as stage, status of surgical margins, and histology are often considered to guide the choice of adjuvant treatment (radiotherapy and/or chemotherapy). In this study, we describe our single-institution experience of three-dimensional conformal PORT administered as adjuvant treatment to patients with thymoma. Methods: Twenty-two consecutive thymoma patients (eleven male and eleven female) with a median age of 52 years and treated at our institution by PORT were analyzed. The patients were considered at high risk of recurrence, having at least one of the following features: stage IIB or III, involved resection margins, or thymic carcinoma histology. Three-dimensional conformal PORT with a median total dose on clinical target volume of 50 (range 44–60) Gy was delivered to the tumor bed by 6–20 MV X-ray of the linear accelerator. Follow-up after radiotherapy was done by computed tomography scan every 6 months for 2 years and yearly thereafter. Results: Two of the 22 patients developed local recurrence and four developed distant metastases. Median overall survival was 100 months, and the 3-year and 5-year survival rates were 83% and 74%, respectively. Median disease-free survival was 90 months, and the 5-year recurrence rate was 32%. On univariate analysis, pathologic stage III and presence of positive surgical margins had a significant impact on patient prognosis. Radiation toxicity was mild in most patients and no severe toxicity was registered. Conclusion: Adjuvant radiotherapy achieved good local control and showed an acceptable toxicity profile in patients with high-risk thymoma. © 2015, Perri et al.
Background: The clinical benefits of postoperative radiation therapy (PORT) for patients with thymoma are still controversial. In the absence of defined guidelines, prognostic factors such as stage, status of surgical margins, and histology are often considered to guide the choice of adjuvant treatment (radiotherapy and/or chemotherapy). In this study, we describe our single-institution experience of three-dimensional conformal PORT administered as adjuvant treatment to patients with thymoma. Methods: Twenty-two consecutive thymoma patients (eleven male and eleven female) with a median age of 52 years and treated at our institution by PORT were analyzed. The patients were considered at high risk of recurrence, having at least one of the following features: stage IIB or III, involved resection margins, or thymic carcinoma histology. Three-dimensional conformal PORT with a median total dose on clinical target volume of 50 (range 44–60) Gy was delivered to the tumor bed by 6–20 MV X-ray of the linear accelerator. Follow-up after radiotherapy was done by computed tomography scan every 6 months for 2 years and yearly thereafter. Results: Two of the 22 patients developed local recurrence and four developed distant metastases. Median overall survival was 100 months, and the 3-year and 5-year survival rates were 83% and 74%, respectively. Median disease-free survival was 90 months, and the 5-year recurrence rate was 32%. On univariate analysis, pathologic stage III and presence of positive surgical margins had a significant impact on patient prognosis. Radiation toxicity was mild in most patients and no severe toxicity was registered. Conclusion: Adjuvant radiotherapy achieved good local control and showed an acceptable toxicity profile in patients with high-risk thymoma. © 2015, Perri et al.
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen
No results. |
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen
Other filter: ([btitle,keywords] "Adjuvant Treatment" ...
Perri F, Addeo R, Conson M, Faiella A, Scarpati GDV, Torre G, Di Biase A, Romanelli P, Buonerba C, Di Lorenzo G, Daponte A, Caponigro F, Pisconti S, Pacelli R, Ravo V, Muto P, Solla R
* Locally advanced paranasal sinus carcinoma: A study of 30 patients (243 views)
Oncol Lett (ISSN: 1792-1074), 2017 Mar; 13(3): 1338-1342.
Impact Factor: 1.664
View Export to BibTeX Export to EndNote
Conson M, Faiella A, Iorio V, Cella L, Liuzzi R, Solla R, Romanelli P, Farella A, Salvatore M, Pacelli R
* Her-2 Subtype And Age Affect Local Control In Breast Cancer (371 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2013; 106: N/D-N/D.
Impact Factor: 4.857
View Export to BibTeX Export to EndNote
Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S
* Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (730 views)
Annals Of Oncology (ISSN: 0923-7534), 2009 May; 20(5): 906-912.
Impact Factor: 5.647
View Export to BibTeX Export to EndNote
* Locally advanced paranasal sinus carcinoma: A study of 30 patients (243 views)
Oncol Lett (ISSN: 1792-1074), 2017 Mar; 13(3): 1338-1342.
Impact Factor: 1.664
View Export to BibTeX Export to EndNote
Conson M, Faiella A, Iorio V, Cella L, Liuzzi R, Solla R, Romanelli P, Farella A, Salvatore M, Pacelli R
* Her-2 Subtype And Age Affect Local Control In Breast Cancer (371 views)
Radiother Oncol (ISSN: 0167-8140, 1879-0887, 1879-0887electronic), 2013; 106: N/D-N/D.
Impact Factor: 4.857
View Export to BibTeX Export to EndNote
Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento MR, De Placido S
* Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study (730 views)
Annals Of Oncology (ISSN: 0923-7534), 2009 May; 20(5): 906-912.
Impact Factor: 5.647
View Export to BibTeX Export to EndNote
3 Records (2 excluding Abstracts).
Total impact factor: 12.168 (7.311 excluding Abstracts).
Total 5 year impact factor: 11.7 (7.03 excluding Abstracts).
Total impact factor: 12.168 (7.311 excluding Abstracts).
Total 5 year impact factor: 11.7 (7.03 excluding Abstracts).
271 views. Last view on Saturday 14 January 2023, 18:04:11
ibb.cnr.it